FLAGU Stock Price, News & Analysis
FLAGU
Company Description
Calidi Biotherapeutics, Inc. (NYSE American: CLDI), a clinical-stage immuno-oncology company, specializes in developing targeted immunotherapies for cancer treatment. With proprietary technology utilizing stem cells to deliver anti-tumor payloads, Calidi aims to revolutionize cancer therapy. Led by CEO Allan Camaisa, the company's cutting-edge platforms, NeuroNova, and SuperNova, focus on high-grade gliomas and solid tumors, offering promising clinical results. Following a successful business combination with First Light Acquisition Group, Calidi is well-positioned to advance its innovative therapies and continue its mission to eradicate cancer.
Stock Performance
$—
0.00%
0.00
Last updated:
- %
Performance 1 year
$0.0
Market Cap
0.0
Shares outstanding
Latest News
SEC Filings
No SEC filings available for FLAGU.
Financial Highlights
—
Revenue (TTM)
—
Net Income (TTM)
—
Diluted EPS (TTM)
—
Operating Cash Flow
—
Net Profit Margin
—
Oper. Profit Margin
Upcoming Events
Frequently Asked Questions
What is Calidi Biotherapeutics known for?
Calidi Biotherapeutics is a clinical-stage immuno-oncology company specializing in developing targeted immunotherapies for cancer treatment.
What are the key platforms of Calidi Biotherapeutics?
Calidi's key platforms are NeuroNova and SuperNova, focusing on high-grade gliomas and solid tumors, respectively.
Who leads Calidi Biotherapeutics?
Calidi Biotherapeutics is led by CEO Allan Camaisa, who is dedicated to advancing innovative cancer therapies.
What is the recent achievement of Calidi Biotherapeutics?
Calidi successfully completed a business combination with First Light Acquisition Group, positioning them to further develop their immunotherapy platforms.
How does Calidi Biotherapeutics aim to revolutionize cancer therapy?
Calidi uses proprietary stem cell technology to deliver anti-tumor payloads, offering targeted and effective cancer treatment options.